| 000 | 01792 a2200505 4500 | ||
|---|---|---|---|
| 005 | 20250518084427.0 | ||
| 264 | 0 | _c20201001 | |
| 008 | 202010s 0 0 eng d | ||
| 022 | _a1934-8576 | ||
| 024 | 7 |
_a10.1002/cpns.88 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aAiravaara, Mikko | |
| 245 | 0 | 0 |
_aBack and to the Future: From Neurotoxin-Induced to Human Parkinson's Disease Models. _h[electronic resource] |
| 260 |
_bCurrent protocols in neuroscience _c03 2020 |
||
| 300 |
_ae88 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Research Support, Non-U.S. Gov't; Review | ||
| 650 | 0 | 4 | _aAnimals |
| 650 | 0 | 4 |
_aCorpus Striatum _xdrug effects |
| 650 | 0 | 4 |
_aDopaminergic Neurons _xdrug effects |
| 650 | 0 | 4 |
_aDrug Evaluation, Preclinical _xmethods |
| 650 | 0 | 4 | _aForecasting |
| 650 | 0 | 4 | _aGenome-Wide Association Study |
| 650 | 0 | 4 | _aHistological Techniques |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aMice |
| 650 | 0 | 4 | _aMice, Transgenic |
| 650 | 0 | 4 |
_aNerve Tissue Proteins _xanalysis |
| 650 | 0 | 4 |
_aNeuroprotective Agents _xtherapeutic use |
| 650 | 0 | 4 |
_aNeurotoxins _xtoxicity |
| 650 | 0 | 4 |
_aParkinson Disease _xgenetics |
| 650 | 0 | 4 |
_aParkinsonian Disorders _xchemically induced |
| 650 | 0 | 4 |
_aPesticides _xtoxicity |
| 650 | 0 | 4 |
_aProtein Aggregation, Pathological _xgenetics |
| 650 | 0 | 4 | _aRats |
| 650 | 0 | 4 |
_aSubstantia Nigra _xdrug effects |
| 650 | 0 | 4 |
_aSynucleinopathies _xgenetics |
| 650 | 0 | 4 |
_aalpha-Synuclein _xbiosynthesis |
| 700 | 1 | _aParkkinen, Ilmari | |
| 700 | 1 | _aKonovalova, Julia | |
| 700 | 1 | _aAlbert, Katrina | |
| 700 | 1 | _aChmielarz, Piotr | |
| 700 | 1 | _aDomanskyi, Andrii | |
| 773 | 0 |
_tCurrent protocols in neuroscience _gvol. 91 _gno. 1 _gp. e88 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1002/cpns.88 _zAvailable from publisher's website |
| 999 |
_c30626055 _d30626055 |
||